Skip to content

Efficacy and Safety of Barphani Ointment in patients suffering from Chronic plaque Psoriasis

An open label, prospective, phase II, clinical study to evaluate efficacy and safety of Barphani Ointment in patients suffering from Chronic Plaque Psoriasis.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020504
Enrollment
30
Registered
2019-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Barphani Ointment: Ayurvedic formulation Control Intervention1: Not applicable: Not applicable

Sponsors

Ayurved Sanshodhan Vibhag
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or Female Subjects in the age group of 18 to 60 years, both inclusive. 2. Subjects with confirmed diagnosis of plaque psoriasis since at least 6 months 3. Subjects must have active plaque psoriasis for atleast 10 % of body surface area. 4. Subjects with plaque psoriasis having PASI score >10 5.Subjects of female gender or non-pregnant, non-lactating females. A urine pregnancy test is required for all female subjects of childbearing potential unless subject has had a hysterectomy, tubal ligation, or is > 2 years postmenopausal. 6.Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Subjects who have received systemic treatment for Psoriasis such as Methotrexate or Cyclosporine therapy or any conventional systemic treatment for more than 4 weeks one month prior to screening in the study. 2. Any laser dermatological procedure, 4 weeks prior to screening in this study 3. Known cases of Severe/Chronic hepatic or renal disease. 4. Known case of any active malignancy. 5. Subjects giving history of significant cardiovascular event to recruitment. 6. Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 7. Subjects participating currently or 1 month prior to recruitment in any other clinical study 8. Known hypersensitivity to any of the ingredients used in study drug 9. Pregnant and Lactating females. 10. Any other condition due to which patients are deemed to be unsuitable by the investigatorâ??s opinion for reason(s) not specifically stated in the exclusion criteria.

Design outcomes

Primary

MeasureTime frame
1.Assessment of changes in PASI Score to measure severity and extend of psoriasis. 2. Assessment of Clinical Photographic changes in psoriasis lesions (Scaling, Intensity and Thickness). Timepoint: 90 days

Secondary

MeasureTime frame
1.Assessment of Quality of life on Dermatology Life Quality Index (DLQI) 2.Assessment of change in Overall Disease Severity (ODS) Score i.e. treatment success. 3. Assessment of Changes in Pruritus Score on the Visual Analogue Scale (VAS) 4. Assessment of relapse of Psoriasis after 30 days of cessation of treatment 5 Assessment of Adverse Drug Reaction 6. Global assessment of overall safety of BARPHANI Ointment 7.subjectâ??s Global Assessment for overall change at the end of study. Timepoint: 90 days

Countries

India

Contacts

Public ContactShishir Purushottam Pande

Department of Rasashastra and BK Ayurved Seva Sanghs Ayurved Mahavidyalaya Nashik

shishir.nsk@gmail.com02532513112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026